is still higher than what other big-selling drugs have achieved historically at similar points following loss of exclusivity. Pfizer noted that after drugs lose market exclusivity, it becomes very difficult for patients to maintain access to branded drugs

PFE) for its recall of 14 lots of Lo/Ovral-28 tablet packs and 14 lots of generic Norgestrel and Ethinyl Estradiol tablets. Pfizer manufactured both drugs and they were marketed in the United States by Akrimax Rx Products under the Akrimax Pharmaceuticals

will intimidate even legitimate generic manufacturers and thereby impact access and availability," said Dilip G. Shah, a former Pfizer executive who now heads both the Indian Pharmaceutical Alliance and the industry's Vision Consulting Group. Activists have

alternatives, but without a ban, there will be far less market pressure to spend money on research for alternatives," he said. Pfizer stopped selling the drug in July after a U.S. Food and Drug Administration study found higher levels of inorganic arsenic

7 (Bloomberg) -- Pfizer Inc.’s breast-cancer drug Aromasin worsened bone loss in post-menopausal women, raising the chance of fractures and calling into question whether the pill’s prevention benefits outweigh its risks. In a trial among 351 women at risk

lots of Lo/Ovral-28 tablets and 14 lots of generic Norgestrel and Ethinyl Estradiol tablets. Both products are manufactured by Pfizer and marketed in the U.S. by Akrimax Rx Products under the Akrimax Pharmaceuticals brand. Pfizer found some packets of the

work for Pfizer in the U.S. and, if so, whether that authorization permits them to work in the job they seek. In no case should Pfizer’s support of a colleague’s temporary visa application or sponsorship of a colleague for permanent residence be construed

work for Pfizer in the U.S. and, if so, whether that authorization permits them to work in the job they seek. In no case should Pfizer’s support of a colleague’s temporary visa application or sponsorship of a colleague for permanent residence be construed

for Pfizer in the U.S. and, if so, whether that authorization permits them to work in the job they seek. In no case should Pfizer’s support of a colleague’s temporary visa application or sponsorship of a colleague for permanent residence be construed to guarantee

in a work assignment in the U. S. For certain classes of temporary visas, the resulting work authorization may be specific to Pfizer and the specific job and/or work site. Pfizer may at its business discretion decide to or refrain from obtaining, maintaining